NCT05169671View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 30, 2022

Primary Completion Date

September 9, 2022

Study Completion Date

September 9, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

ATH-1020

ATH-1020 in oral capsule form

DRUG

Placebo

Placebo in oral capsule form

Trial Locations (1)

07103

Biotrial, Inc., Newark

Sponsors

Lead Sponsor

Athira Pharma
All Listed Sponsors
collaborator

Biotrial Inc.

UNKNOWN

collaborator

Alturas Analytics, Inc.

UNKNOWN

lead

Athira Pharma

INDUSTRY

NCT05169671 - Safety, Tolerability, and Pharmacokinetics Study of ATH-1020 | Biotech Hunter | Biotech Hunter